This content is unpublished, click the edit tab and check "Published" on the bottom of the form.
28.
09.15
06:58
Close share menu
New data from KEYNOTE-028, the MSD study for the testing of KEYTRUDA (Pembrolizumab) with various types of cancer, at the European Cancer Congress 2015 presented